Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12986 | 0.82 | RECQL (0.63) | KMT2AMEN1POLBALDH1A1CHRNB2 | |
| SCHEMBL12449663 | 0.82 | RECQL (0.63) | KMT2AMEN1POLBALDH1A1CHRNB2 | |
| SCHEMBL19002209 | 0.82 | RECQL (0.63) | KMT2AMEN1POLBALDH1A1CHRNB2 | |
| SCHEMBL10099560 | 0.81 | HPGD (0.54) | KMT2APOLBALDH1A1HPGDRECQL | |
| SCHEMBL12261870 | 0.81 | HPGD (0.54) | KMT2APOLBALDH1A1HPGDRECQL | |
| SCHEMBL18082875 | 0.79 | ALDH1A1 (0.54) | KMT2AMEN1POLBALDH1A1CHRNB2 | |
| SCHEMBL21776398 | 0.79 | ALDH1A1 (0.54) | KMT2AMEN1POLBALDH1A1CHRNB2 | |
| SCHEMBL18997081 | 0.79 | ALDH1A1 (0.54) | KMT2AMEN1POLBALDH1A1CHRNB2 | |
| SCHEMBL19002214 | 0.79 | ALDH1A1 (0.54) | KMT2AMEN1POLBALDH1A1CHRNB2 | |
| SCHEMBL23844428 | 0.78 | KMT2A (0.64) | KMT2AMEN1POLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | KMT2A 3181/4885MEN1 3536/4885POLB 1722/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | KMT2A 3544/4885MEN1 4080/4885POLB 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.